ICU Medical, Inc.
ICU Medical, Inc. (ICUI) Financial Performance & Income Statement Overview
View comprehensive annual and quarterly summaries for ICU Medical, Inc. (ICUI), featuring income statements, balance sheets, and cash flow data.
ICU Medical, Inc. (ICUI) Income Statement & Financial Overview
Review ICU Medical, Inc. ICUI income statement with detailed quarterly and annual figures.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $604.70M | $629.80M | $589.13M | $596.46M |
| Cost of Revenue | $394.59M | $402.55M | $384.28M | $389.03M |
| Gross Profit | $210.11M | $227.26M | $204.85M | $207.43M |
| Gross Profit Ratio | $0.35 | $0.36 | $0.35 | $0.35 |
| R&D Expenses | $23.29M | $22.36M | $21.03M | $23.39M |
| SG&A Expenses | $157.23M | $158.85M | $162.71M | $159.55M |
| Operating Expenses | $197.22M | $189.57M | $196.62M | $199.74M |
| Total Costs & Expenses | $591.81M | $607.23M | $580.89M | $588.76M |
| Interest Income | $0.00 | $2.73M | $2.60M | $2.81M |
| Interest Expense | -$22.03M | $26.19M | $27.29M | $26.65M |
| Depreciation & Amortization | $0.00 | $52.99M | $55.60M | $55.32M |
| EBITDA | $12.89M | $87.42M | $64.96M | $79.81M |
| EBITDA Ratio | $0.02 | $0.14 | $0.11 | $0.13 |
| Operating Income | $12.89M | $37.69M | $8.24M | $7.69M |
| Operating Income Ratio | $0.02 | $0.06 | $0.01 | $0.01 |
| Other Income/Expenses (Net) | -$23.79M | -$29.47M | -$26.16M | -$27.23M |
| Income Before Tax | -$10.91M | $8.22M | -$17.93M | -$19.53M |
| Income Before Tax Ratio | -$0.02 | $0.01 | -$0.03 | -$0.03 |
| Income Tax Expense | -$4.57M | $32.05M | $15.05M | $1.87M |
| Net Income | -$15.48M | -$23.83M | -$32.98M | -$21.41M |
| Net Income Ratio | -$0.03 | -$0.04 | -$0.06 | -$0.04 |
| EPS | -$0.63 | -$0.97 | -$1.35 | -$0.88 |
| Diluted EPS | -$0.63 | -$0.97 | -$1.35 | -$0.88 |
| Weighted Avg Shares Outstanding | $24.54M | $24.49M | $24.44M | $24.39M |
| Weighted Avg Shares Outstanding (Diluted) | $24.54M | $24.49M | $24.44M | $24.39M |
The company's financials show resilient growth, with revenue advancing from $596.46M in Q2 2024 to $604.70M in Q1 2025. Gross profit remained healthy with margins at 35% in Q1 2025 compared to 35% in Q2 2024. Operating income hit $12.89M last quarter, sustaining a consistent 2% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at $12.89M. Net income rose to -$15.48M, while earnings per share reached -$0.63. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan